Stable dry powder inhaler formulation of tranilast attenuated antigen-evoked airway inflammation in rats.

@article{Kawabata2011StableDP,
  title={Stable dry powder inhaler formulation of tranilast attenuated antigen-evoked airway inflammation in rats.},
  author={Yohei Kawabata and Yosuke Aoki and Takuya Matsui and Kiyoshi Yamamoto and Hideyuki Sato and Satomi Onoue and Shizuo Yamada},
  journal={European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V},
  year={2011},
  volume={77 1},
  pages={178-81}
}
Tranilast (TL) has been clinically used for the treatment of airway inflammatory diseases, although the clinical use of TL is limited because of its poor solubility and systemic side effects. To overcome these drawbacks, a novel respirable powder of TL (CSD/TL-RP) for inhalation therapy was developed using nanocrystal solid dispersion of TL (CSD/TL… CONTINUE READING